A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...

A metro medical care provider was diagnosed with glioblastoma–one of the most aggressive forms of cancer–and is using it as an opportunity to contribute to cancer research. So much of Jenny McMillan’s ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling drug Biktarvy in a late-stage trial. The experimental regimen could expand ...

Overall, higher income increased a person’s odds of joining a clinical trial up to 67%, researchers found. Likewise, ...

An experimental drug could help to improve movement for patients with spinal cord injuries. NVG-291, an injectable peptide, has been tested in a phase 2 trial with eligible patients — some of whom ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by Eli Lilly could offer an intriguing off-ramp.

June 23 (Reuters) - In a mid-stage trial, the highest dose of Eli Lilly's LLY.N experimental pill orforglipron led to 14.7% weight loss after 36 weeks for people who were obese or overweight, setting ...

(Reuters) -The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV treatments due to low levels of a type of white blood cell in ...

An experimental weight loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothold in the ...

An experimental vaccine for acne could someday transform the way patients with the condition are treated, according to the company that developed the shot. However, it is still early days. When you ...

The Food and Drug Administration has increasingly exercised its power to delay drug companies’ testing of experimental drugs in recent years, a possible byproduct of newer medical technologies that ...